Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp435 | Osteoporosis: treatment | ECTS2013

Denosumab's dynamic CTX profile is maintained over 6 years of treatment: first 3 years of the FREEDOM extension study

Roux C , McClung MR , Franchimont N , Adami S , Ebeling PR , Reid IR , Resch H , Weryha G , Daizadeh N , Wang A , Wagman RB , Eastell R

Denosumab (DMAb) has a unique profile of bone resorption inhibition: CTX decreases rapidly by 3 days and inhibition is released at the end of the 6-month dosing interval, when DMAb serum levels decrease (McClung NEJM 2006). The dynamic CTX inhibition profile is not curtailed by continued treatment. In the 3-year FREEDOM study, CTX values at 6 months were influenced by baseline CTX values and days since the 1st injection (Eastell JBMR 2011). With 3 additional ...

ba0001pp416 | Osteoporosis: treatment | ECTS2013

Meta-analysis of the effects of vitamin D supplements on bone mineral density in adults

Reid Ian R , Bolland Mark , Grey Andrew

Recent meta-analyses of vitamin D without co-administration of calcium have not demonstrated fracture prevention, possibly through lack of power, inappropriate choice of doses, or failure to target the intervention to deficient populations. Bone mineral density (BMD) is able to detect biologically significant effects in much smaller cohorts, so is a relevant surrogate measure with which to re-assess the skeletal efficacy of these supplements. We searched Web of Science, Embase...

ba0001pp35 | Bone biomechanics and quality | ECTS2013

The effect of fluoride on the DEXA score and material properties of ex vivo emu tibiae

Omelon Sidney , Nhan Kevin , Reid-Schachter Gillian , Lacroix Nicolas , Miles-Rossouw Malaika , Variola Fabio

Bone is a tough composite material, comprised of a compliant collageneous matrix, brittle apatite mineral crystals and a suite of non-collageneous proteins (NCPs). Bone material properties depend on these components, and their interactions at the mineral-collagen interface. ‘Bone mineral density’ (BMD), a parameter used to predict fracture risk, is routinely quantified by DEXA. Previous studies used ex vivo emu tibiae as a model to test the effect of organic...

ba0005oc1.2 | Clinical trials and osteoporosis treatment | ECTS2016

Acute effects of calcium supplements on blood pressure: results of a randomised cross-over trial

Bristow Sarah , Billington Emma , Gamble Greg , de Kwant Jordyn , Stewart Angela , Horne Anne , Reid Ian

Calcium supplements are associated with increased cardiovascular risk, but the mechanism by which this occurs is presently uncertain. In a secondary analysis of a trial examining the acute effects of calcium supplements, we found that blood pressure declined over 8 h in the control group, consistent with its diurnal rhythm, and that this decline was smaller in the calcium group [1]. To investigate these effects further, we carried out a randomised controlled cross-over trial o...

ba0006p029 | (1) | ICCBH2017

Web-based surveys using Patient-Reported Outcome Measurement Information System (PROMIS) instruments allow documentation of important components of the disease experience among individuals with Osteogenesis Imperfecta

Tosi Laura , Floor Marianne , Holland Rosalie , Goerlich Cara , Hart Tracy , Cuthbertson David , Sutton V Reid , Krischer Jeffrey

Objectives: Two important goals of the Rare Diseases Clinical Research Network Brittle Bone Disorders Consortium (RDCRN BBD) are i) to perform collaborative clinical research in brittle bone disorders including a longitudinal observational study driven by genotypic association and ii) to explore use of the PROMIS tool to provide valid quality of life (QOL) measures in individuals with Osteogenesis Imperfecta (OI). This work has been motivated by the fact that all current outco...

ba0001pp434 | Osteoporosis: treatment | ECTS2013

Bone histology and histomorphometry: effects of 5 years of denosumab in the FREEDOM Extension

Brown Jacques P , Wagman Rachel , Dempster David W , Kendler David , Miller Paul , Bolognese Michael , Valter Ivo , Beck Jensen Jens-Erik , Zerbini Cristiano , Zanchetta Jose R , Daizadeh Nadia , Reid Ian

DMAb increases BMD and reduces bone resorption and risk of vertebral, nonvertebral and hip fractures in women with PMO. Transiliac crest bone biopsies in 47 subjects treated with DMAb for 1–3 years showed reduced bone turnover vs 45 Pbo-treated subjects, which reversed on treatment cessation. Since bone turnover reduction is sustained and fracture incidence low over 6 years’ DMAb treatment, we evaluated DMAb’s effects on tissue-level remodelling in the FREEDOM E...

ba0005ht4 | (1) | ECTS2016

Vitamin D supplementation in pregnancy leads to greater bone mass in UK infants born during winter months: the MAVIDOS multicentre, randomised, double-blind, placebo-controlled trial

Cooper Cyrus , Harvey Nicholas , Bishop Nicholas , Kennedy Stephen , Papageorghiou Aris , Schoenmakers Inez , Fraser Robert , Gandhi Saurabh , D'Angelo Stefania , Crozier Sarah , Moon Rebecca , Arden Nigel , Dennison Elaine , Godfrey Keith , Inskip Hazel , Prentice Ann , Mughal Zulf , Eastell Richard , Reid David , Javaid Kassim

Maternal vitamin D status has been positively associated with infant bone mass in observational studies. We therefore evaluated whether 1000 IU/day cholecalciferol during pregnancy would lead to greater offspring bone mass at birth, in a UK, multicentre, randomised, double-blind, placebo-controlled trial (MAVIDOS, ISRCTN82927713).At 12 weeks’ gestation, pregnant women with a serum 25-hydroxyvitamin D [25(OH)D] 25-100 nmol/l were randomised to either...

ba0005oc3.2 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Effects of Denosumab (Dmab) on bone matrix mineralization: results from the phase 3 FREEDOM trial

Dempster David W , Brown Jacques P , Yue Susan , Farlay Delphine , Rizzo Sebastien , Song Jenny , Wang Andrea , Wagman Rachel B , Boivin Georges

Low fracture (FX) incidence has been demonstrated in women with postmenopausal osteoporosis (PMO) treated with DMAb for up to 10 years in the FREEDOM extension [Bone ASBMR 2015]. Bone biopsy-based assessment of DMAb’s effects at the tissue level has demonstrated a low remodelling rate consistent with DMAb’s mechanism of action (Reid JBMR 2010; Brown JBMR 2014). From FREEDOM, we report the effects of DMAb on bone matrix mineralization in women who un...

ba0005p345 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

The effects of 60-day sodium glutamate intake and exposure to ionizing radiation on ultrastructure of biomineral of the ramus of mandible in rats

Simrok Ksenia , Luzin Vladyslav , Miakotkyna Galyna , Skryabina Elena

Objectives: The study is aimed at investigation of ultrastructure of biomineral of the ramius of mandible (BRM) in rats after application of sodium glutamate (SG) and exposure to ionizing radiation (IR), and finding possibility of medication with Spirulina (SP).Methods: The experiment involved 240 rats with body weight of 180–200 g. The animals were distributed into eight groups as follows: intact animals for the controls, animals that received ...